Search
forLearn
5 / 801 resultslearn Vitamin F
learn LHA™
learn APISCALP™
learn mometasone furoate
Research
5 / 51 results
research Gynecologic and andrologic dermatology and the metabolic syndrome
Skin diseases linked to insulin resistance should be managed to prevent diabetes and reduce heart disease risk.
research Facial Psoriasis Log-based Area and Severity Index: A valid and reliable severity measurement method detecting improvement of facial psoriasis in clinical practice settings
The Facial Psoriasis Log-based Area and Severity Index is a more effective way to measure improvements in facial psoriasis than the traditional method.
research Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis
PRP can increase hair density in women with hair loss, but more research is needed.
research The analysis of scalp irritation by coacervates produced in hair shampoo via FTIR with focal plane array detector, X‐ray photoelectron microscopy and HaCaT cells
Shampoo coacervates can cause scalp irritation due to released surfactants.
research A case of feline paraneoplastic alopecia with secondary Malossezia‐associated dermatitis
Malassezia-associated dermatitis can cause itching in cats with feline paraneoplastic alopecia.
Community Join
5 / 1000+ resultscommunity Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
community P5P supplementation for fin sides.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.